Trieste, 9 December 2024 - The microbiome market is at the start of a turning point, with groundbreaking research and growing consumer awareness driving double-digit market growth. While the scientific world is increasingly focusing on explaining the intricate relationship between the human microbiome and overall health, the market for microbiome-based products and services is set to reach new heights.
For reference, the global gut microbiota market is expected to register a CAGR of 17.1% from 2024 to 2033. In 2024, the market size is expected to reach a valuation of $717.2 million. By 2033, the valuation is expected to reach $2,969.4 million (source).
The microbiota, composed of trillions of microorganisms living inside and outside our bodies, plays a crucial role in various bodily functions, including digestion, immunity and mental health. Recent advances in microbiota research have revealed the potential of targeting the microbiota to prevent and treat a wide range of diseases, from digestive disorders to autoimmune diseases.
The main factors driving the growth of the microbiota market include:
- Growing consumer interest in gut health: Consumers are increasingly seeking natural and holistic approaches to health, leading to increased demand for probiotics, prebiotics and other products that support the microbiota.
- Advances in microbiota research: Ongoing research is revealing new insights into the microbiota-gut-brain axis, microbiota-immunity interactions and the role of the microbiota in chronic diseases.
- Development of personalised microbiota therapies: Personalised microbiota-based treatments are emerging, offering the potential for more effective and personalised healthcare. - Increased investment in microbiota companies: Venture capital and pharmaceutical companies are investing heavily in microbiota start-ups, fuelling innovation and accelerating the development of new products and services.
The Group is strategically positioning itself to become an emerging leader in the microbiota sector. With a specific focus on microbiota testing and diagnostics, Ulysses Biomed and Hyris, Group companies, are leveraging their proprietary platform of medical hardware, software and reagents together with their technological capabilities to bring new targeted and cost-effective tests to this innovative and evolving field.
An example of this positioning is the partnership started in May 2024 with Gutsy (website), a North American company active in microbiota testing. Gutsy, a leader in qPCR applications for the microbiota, has chosen Ulysses Biomed and its proprietary Hyris System™ for the targeted development and large-scale distribution of direct-to-consumer tests, starting with metabolic syndrome and expanding to more targeted microbiota tests. Initial results to date on the first test are proving convincing and, in collaboration with Ulysses Biomed, new tests are already in the pipeline to be launched within the next year.
"We strongly believe in this application area, which has yet to unleash its true impact," says Lorenzo Colombo, CTO of Ulisse Biomed. "We have started with gut microbiota testing, but we are already approaching other application areas, for example women's health and vaginal microbiota, considering the obvious synergies and complementarities with our current main focus, i.e. papilloma virus and STI testing."
"We are committed and ready to seize new opportunities in this field," adds Gabriele Salaris, Head of Marketing & Sales at Ulisse Biomed. "We expect this application area to be an important growth engine for the group's revenues in the coming years," Salaris concludes.
